Elon Musk and Sam Altman's OpenAI have agreed to expedite a trial to hear their dispute over the company's for-profit ...

A clinical trial involves the study of the safety, efficacy and/or dosage regimen of a therapeutic intervention (such as a drug) in humans selected according to predetermined criteria of ...

Updated Phase 1 data for ELVN-001 expected mid-2025 as positive enrollment momentum continues Expected monotherapy and combination data from the ELVN-002 Phase 1 trials ...

Recently announced positive data from pivotal randomized, placebo-controlled phase 3 clinical trial of CAN-2409 in ...

Monogram Technologies Inc. ( NASDAQ: MGRM) Q4 2024 Earnings Conference Call March 11, 2025 4:30 PM ET Larry Holub - Investor Relations Benjamin Sexson - Chief Executive Officer Noel Knape - Chief ...

The latest development in the Synapse saga provides a few new clues but leaves many questions unanswered about missing ...

Company generated quarterly sequential growth in YCANTH® dispensed applicator units of 12.3% in Q4’24 concurrent with significantly lower ...

Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) Q4 2024 Earnings Call Transcript March 6, 2025 Atea Pharmaceuticals, Inc. misses on ...

A federal judge refused to give Musk an immediate injunction against OpenAI's switcheroo, but threw him a lifeline.

Record Year with Total 2024 Revenues of $161.0 Million, Representing a 13% Increase over Fiscal Year 2023 and Adjusted EBITDA of $34.1 Million, Up 42% Year-over-Year, and a 21% Margin of RevenuesCash ...

Topline interim dataset from GALAXIES Lung-201 with >240 patients anticipated in 2Q25- Interim datasets from GALAXIES H&N-202 and ...